Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Accumulated Expenses: 2012-2025

Historic Accumulated Expenses for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to $30.7 million.

  • Enanta Pharmaceuticals' Accumulated Expenses fell 10.89% to $30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.7 million, marking a year-over-year decrease of 10.89%. This contributed to the annual value of $30.7 million for FY2025, which is 10.89% down from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Accumulated Expenses of $30.7 million as of Q3 2025, which was up 10.65% from $27.8 million recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Accumulated Expenses registered a high of $36.7 million during Q2 2023, and its lowest value of $15.2 million during Q4 2022.
  • Moreover, its 3-year median value for Accumulated Expenses was $32.7 million (2024), whereas its average is $31.5 million.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Accumulated Expenses slumped by 42.95% in 2022, and later spiked by 140.80% in 2023.
  • Quarterly analysis of 5 years shows Enanta Pharmaceuticals' Accumulated Expenses stood at $26.6 million in 2021, then slumped by 42.95% to $15.2 million in 2022, then spiked by 140.80% to $36.5 million in 2023, then declined by 10.32% to $32.7 million in 2024, then fell by 10.89% to $30.7 million in 2025.
  • Its last three reported values are $30.7 million in Q3 2025, $27.8 million for Q2 2025, and $30.7 million during Q1 2025.